GLP 1 menstrual cycle study links dual incretin drugs to shorter cycles
Apple Women's Health Study data presented at ASRM link combined GLP 1 and GIP drugs with cycles that shortened by 2.5 days and varied slightly less, with the largest gap in PMOS. The cohort is self reported and observational.
What's new
An Apple Women's Health Study analysis of 1,945 women presented at ASRM linked combined GLP 1 and GIP drug use in the past year with shorter, slightly less variable menstrual cycles.
Why it matters
The researchers said no earlier prospective study had made cycle regularity a primary endpoint for these drugs. The largest gap was in women with PMOS, but the data are observational and self reported.
What's next
Mahalingaiah said future manuscripts will break the data down by individual drug. No regulator has assessed these drugs for cycle effects.
BALTIMORE. Women who reported using a combined GLP 1 and GIP receptor agonist logged menstrual cycles that shortened by 2.5 days on average, against 0.4 days for GLP 1 users and 0.8 days for never users, according to a GLP 1 menstrual cycle analysis presented at the American Society for Reproductive Medicine annual meeting. MedPage Today reported the data, which come from the Apple Women's Health Study. The study is observational. It shows an association, not proof that the drugs changed anyone's cycle.
What the ASRM analysis found
A team at Harvard's public health school, led by Shruthi Mahalingaiah, MD, MS, ran the analysis, according to the MedPage Today report. Her team asked whether these drugs were linked to changes in two measures: mean cycle length and how much cycles varied within the same person. Users of the combined drug class saw the largest drop in cycle length. Users of a GLP 1 drug alone saw a smaller drop of 0.4 days, close to the 0.8 day drop among women who had never used either drug. The report does not give starting cycle lengths for each group. Without them, readers cannot tell whether a 2.5 day change moved cycles toward a typical range or simply shortened them.
The second measure, mean individual cycle variability, tells how much a woman's cycle length shifts from one month to the next. A lower figure means a more predictable cycle. The researchers reported 6.93 days for combined drug users, 7.45 days for GLP 1 users and 7.46 days for never users. That gap of about half a day is modest, and the report gives no confidence intervals or p values to show how certain it is. Mahalingaiah said earlier retrospective studies had hinted at better cycle regularity on these drugs, but none had tracked cycles forward in time with regularity as a primary endpoint. "We wanted to show, with a little more granularity, the extent to which we might see impact," she told MedPage Today.
| Measure reported | GLP 1 and GIP users | GLP 1 users | Never users |
|---|---|---|---|
| Participants | 123 | 258 | 1,564 |
| Drop in mean cycle length | 2.5 days | 0.4 days | 0.8 days |
| Mean individual cycle variability, all | 6.93 days | 7.45 days | 7.46 days |
| Mean individual cycle variability, PMOS | 5.80 days | 7.34 days | 9.45 days |
How the Apple cohort was built
The Apple Women's Health Study follows roughly 147,000 women in the United States who record each period in an app as it happens, according to the report. Members are 18 or older, own an iPhone and have had at least one period. For this GLP 1 menstrual cycle analysis, the team kept only women younger than 50 who were not pregnant, not breastfeeding and not using hormones. Each had to have logged at least three cycles, and each cycle had to fall between 10 and 90 days. Participants also answered surveys on weight loss drugs, demographics and medical history. They agreed to share cycle logs stored in Apple's HealthKit, though the authors said they set aside all sensor based data.
Without them, readers cannot tell whether a 2.5 day change moved cycles toward a typical range or simply shortened them.
After those filters, 1,945 women with 70,134 logged cycles remained. Of these, 1,564 had never used the drugs, 258 had used a GLP 1 medicine and 123 had used a combined GLP 1 and GIP medicine in the past year. Drug use was self reported, and the report does not say which products the women took or for how long. Weight loss for health was the top reason for a prescription, ahead of weight loss for looks and then PMOS. In the United States, tirzepatide, sold for weight loss as Zepbound, is the only GLP 1 and GIP drug the FDA has approved, the report noted. Mahalingaiah said later papers will split the results by individual drug.
PMOS subgroup shows the widest gap
The widest gaps appeared in women with polyendocrine metabolic ovarian syndrome, or PMOS, the condition formerly called polycystic ovary syndrome. In this subgroup, combined drug users had a mean individual cycle variability of 5.80 days, against 7.34 days on GLP 1 drugs and 9.45 days in women who never took either, the researchers reported. Mahalingaiah said the larger effect in PMOS might point to a separate pathway acting on ovulation itself, beyond the metabolic gains that support ovulation. She added that more research is needed. The report does not give the number of women with PMOS in each drug group. Small subgroups can produce large differences by chance, so the PMOS figures carry more uncertainty than the headline result for all participants.
Rachel Weinerman, MD, who works in Cleveland as a reproductive endocrinologist with Case Western Reserve University and had no role in the study, called the PMOS findings particularly interesting, MedPage Today reported. She said PMOS is a metabolic condition, so weight loss can help patients reach a more regular cycle. On that view, a patient with PMOS who takes a weight loss drug would be expected to lose weight and see more regular periods at the same time. Weinerman also said irregular periods matter beyond fertility because they can signal other health problems. She said the study is a reminder that PMOS patients form their own group and may react to medicines unlike others with similar traits.
Limits of the data and what comes next
The groups were not alike at the start. Drug users were older, at 38 to 39 years against 35 for never users, and had more prior births. They also had higher rates of PMOS, infertility, type 2 diabetes and high blood pressure, the report said. Those differences could shape cycle patterns on their own. The report does not say whether the team adjusted for weight change, age or other factors. The combined drug group had only 123 women. The findings come from a presentation at the ASRM annual meeting, and the report does not mention a peer reviewed paper. No regulator has assessed these drugs for cycle regularity, and this GLP 1 menstrual cycle signal is not a reason to start or change treatment.
The data touch on a live question for women of reproductive age who use these drugs. The American College of Obstetricians and Gynecologists has advised stopping GLP 1 drugs before conception and avoiding them in pregnancy, citing limited safety data. The new analysis reports no pregnancy or fertility outcomes. The report describes only logged cycle dates, not ovulation tests or hormone levels. Other tirzepatide signals have also come from observational sources, such as a health records study on mood, and such findings need trials to confirm them. Mahalingaiah said she hopes data like these lead drug makers to study how such medicines might promote ovulation, noting there is "such little innovation in women's health pharmaceuticals."
Conclusion
This GLP 1 menstrual cycle analysis links combined GLP 1 and GIP drug use with shorter and slightly steadier cycles, with the clearest gap in women with PMOS. It is a self reported cohort result from a conference, not a trial, and the groups differed at baseline. The next step, according to Mahalingaiah, is a breakdown by individual drug. Readers can follow coverage of new readouts on the Peptide Zone trials desk. This story is research news and not medical advice.
